CLINICAL TRIALS PROFILE FOR PROTONIX IV
✉ Email this page to a colleague
All Clinical Trials for Protonix Iv
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00133770 ↗ | Intravenous (IV) Pantoprazole in Erosive Esophagitis | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 | 2004-07-01 | The aim of this study is to examine whether pantoprazole (Protonix) given through continuous intravenous infusion for 72 hours is superior to Protonix given through once a day IV injection in the treatment of erosive esophagitis. |
| NCT00133770 ↗ | Intravenous (IV) Pantoprazole in Erosive Esophagitis | Completed | Emory University | Phase 4 | 2004-07-01 | The aim of this study is to examine whether pantoprazole (Protonix) given through continuous intravenous infusion for 72 hours is superior to Protonix given through once a day IV injection in the treatment of erosive esophagitis. |
| NCT00206050 ↗ | Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po | Completed | AstraZeneca | Phase 4 | 2004-09-01 | This Phase IV study is intended to compare intragastric acid suppression of oral esomeprazole (NEXIUM ® Delayed-Release Capsules) with that of oral pantoprazole (PROTONIX ® Delayed Release Tablets ), in subjects who continue to require acid-suppressive therapy following a course of intravenous (iv) pantoprazole (PROTONIX ® I.V. for Injection). |
| NCT00625274 ↗ | A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients | Completed | AstraZeneca | Phase 4 | 2004-06-01 | This study looks at controlling intragastric pH following administration of esomeprazole 40 mg, lansoprazole 30 mg and pantoprazole 40 mg taken orally, once daily in patients taking either non-selective or cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drugs (NSAIDs). |
| NCT00674245 ↗ | Effect of Pantoprazole 40mg Daily vs Placebo on Power Spectral Analysis of the Sleep EEG of Patients With GERD. | Completed | Southern Arizona VA Health Care System | Phase 2/Phase 3 | 2008-04-01 | The purpose of this research study is to determine if treatment with pantoprazole 40 mg daily versus a placebo improves sleep quality in patients with gastroesophageal reflux disease (GERD). Another purpose is to determine if treatment with pantoprazole 40 mg once daily versus a placebo improves sleep outcomes in patients with gastroesophageal reflux disease using spectral analysis of sleep electroencephalogram (EEG). |
| NCT00699361 ↗ | Influence of Pantoprazole on Human Myocardial Contractility at Patients With Congestive Heart Failure | Withdrawn | Johann Wolfgang Goethe University Hospital | Phase 3 | 2008-08-01 | Recently literature revealed facts, that show H+/K+ ATPase expression is not limited tot he stomach. H+/K+ ATPase was also found in smooth muscle cells and in other tissues (McCabe, R.D. et al., Am J Physiol. 1992). For myocard a localisation is only proven for rats yet (Beisvag, V. et al., Acta Physiol Scand. 2003). Moreover biochemical hints lead us to a highly probability of a myocardial H+/K+ ATPase (Nagashima, R. et al., Jpn Heart J. 1999). |
| NCT00744419 ↗ | Intravenous (IV) Pantoprazole for Gastroesophageal Reflux Disease (GERD) in Neonates and Infants | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 | 2009-05-01 | The purpose of this study is to determine how the body uses and eliminates pantoprazole, a drug used to treat GERD. This is a pharmacokinetic (PK) study. PK is a measure of how much drug is in the blood and how long it takes to leave the body. It is hypothesized that younger infants will need a lower dose than older children to achieve the same PK measurement. The results of this study will be used to determine the best dose of the drug to use in each age group. Pantoprazole is a drug used to decrease acid production. The use of pantoprazole has not been approved for use in children. Pantoprazole is approved for use of acid-related and stomach disorders in adults. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Protonix Iv
Condition Name
Clinical Trial Locations for Protonix Iv
Trials by Country
Clinical Trial Progress for Protonix Iv
Clinical Trial Phase
Clinical Trial Sponsors for Protonix Iv
Sponsor Name
